The US Food and Drug Administration (FDA) is set to announce the first medical cannabis products that can be safely marketed and sold under the law.
According to the National Cannabis Industry Association (NCIA), the products will come from two US companies, but it has not yet been announced what they will be.
The NCIA says the products, which are expected to be available for sale on July 1, will be “high-tech cannabis products, infused with CBD oil” and will be made by three firms.
“We are excited about the potential of this new type of cannabis products and want to make sure we are following the best practices in the cannabis industry to make it safe and effective for patients and consumers,” NCIA’s vice president of regulatory affairs, Michael Schoen, said in a statement.
“Our goal is to work closely with the FDA to make these products safe and accessible to patients, while ensuring that there are clear standards for compliance.”
The products will be marketed under the name Medicinal Cannabis, according to the company’s website.
It will be sold under an exclusive brand called “Mushroom & Co”.
“As we know, marijuana is a popular and highly effective medical treatment and we are looking forward to bringing this new product to patients in the states where it will be legal,” a spokesperson for the company said in the statement.
According for a 2015 report from The Washington Post, a company called “Beverage Solutions” had a patent application for the product that was awarded in February.
The company said the product is designed to reduce nausea and anxiety in people with cancer and glaucoma, which have severe side effects.
A spokesperson for B&S told Business Insider it was not available to market in the US at this time.
In August, the FDA also approved the use of cannabidiol, the main ingredient in cannabis.
This means that if a patient or caregiver needs a medical cannabis product, they will not have to go through the FDA process.
However, the company did not say how it would manage the legalisation of medical cannabis, and it was unclear if it would provide financial assistance to patients who needed it.
The US Food & Drug Administration is set not to issue a final regulatory ruling on the use and distribution of medical marijuana until late 2018.
The FDA is also set to issue guidance on the future use of medical products in the future.